Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?

To the Editor:

We congratulate Drake and colleagues for their timely, international multicenter study of outcomes of hospitalization for coronavirus disease (COVID-19) in people with interstitial lung disease (ILD) (1). This found that 161 people with ILD were at increased risk of death (COVID-19) in people with interstitial lung disease (ILD) (1). This multicenter study of outcomes of hospitalization for coronavirus disease COVID-19 test (5). A Korean nationwide cohort study with propensity score matching studied a potential role for PPIs as a risk in COVID-19 test (5). Regression analysis showed that individuals using PPIs up to once a day (odds ratio, 2.15; 95% CI, 1.90–2.44) or twice daily (odds ratio, 3.67; 95% CI, 2.93–4.60) had significant, PPI dose response–associated, increased odds for reporting a positive COVID-19 test (5). A Korean nationwide cohort study with propensity score matching studied a potential role for PPIs as a risk in severe COVID-19, including 132,316 people tested for SARS-CoV-2. In confirmed COVID-19, the current use of PPIs conferred a 79% greater risk of severe clinical outcomes (6).

We suggest that PPI treatment may have been taken by many of the people with IPF in the study from Drake and colleagues, with the potential that the control group systematically had less exposure. We wonder if the authors were able to consider this in their analyses or have data that might inform this. We would be very interested in the authors’ expert opinion on the potential role of “aerodigestive” pathophysiology in their findings.

Author disclosures are available with the text of this letter at www.atajournals.org.

Abdullah Althuwaybi, M.Sc.
Maher Al Qua’im, M.Sc.
Newcastle University
Newcastle upon Tyne, United Kingdom

References

1. Carden KA, Boiselle PM, Waltz DA, Ernst A. Tracheomalacia and tracheobronchomalacia in children and adults: an in-depth review. Chest 2005;127:984–1005.
2. Boiselle PM, Michaud G, Roberts DH, Loring SH, Womble HM, Millett ME, et al. Dynamic expiratory tracheal collapse in COPD: correlation with clinical and physiologic parameters. Chest 2012;142:1539–1544.
3. Jokinen K, Palva T, Sutinen S, Nuutinen J. Acquired tracheobronchomalacia. Ann Clin Res 1977;9:52–57.
4. Bhatt SP, Terry NLJ, Hath S, Zach JA, Tschiren J, Bolding MS, et al. Genetic Epidemiology of COPD (COPDGene) Investigators. Association between expiratory central airway collapse and respiratory outcomes among smokers. JAMA 2016;315:498–505.
5. Shah V, Husta B, Mehta A, Ashok S, Ishikawa O, Stoffels G, et al. Association between inhaled corticosteroids and tracheobronchomalacia. Chest 2020;157:1426–1434.
6. Mehta AC, Zaki KS, Banga A, Singh J, Gildea TR, Arrossi V. Tracheobronchial smooth muscle atrophy and separation. Respiration 2019;105:256–262.
7. Husta BC, Raoof S, Erzurum S, Mehta AC. Tracheobronchopathy from inhaled corticosteroids. Chest 2015;127:1306S–1307S.
8. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD 2010;7:32–43.
9. Graham BL, Steenbruggen I, Miller MR, Barjaktaarevic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update: an American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 2019;200:e70–e88.
10. Copeland CR, Hath S, Terry NLJ, Wilson CG, Kim YI, Lynch DA, et al.; Genetic Epidemiology of COPD (COPDGene) Investigators. Paratracheal paraseptal emphysema and expiratory central airway collapse in smokers. Ann Am Thorac Soc 2018;15:479–484.

Correspondence

Surya P. Bhatt, M.D., M.S.P.H.*
University of Alabama at Birmingham
Birmingham, Alabama

ORCID IDs: 0000-0001-6984-9860 (T.H.H.); 0000-0002-8418-4497 (S.P.B.).

*Corresponding author (e-mail: sbhatt@uabmc.edu).

Copyright © 2021 by the American Thoracic Society.
Amaran Krishnan, M.D.
Newcastle University
Newcastle upon Tyne, United Kingdom

and
York Teaching Hospital NHS Foundation Trust
York, United Kingdom

Rhys Jones, M.D.
The James Cook University Hospital
Middlesbrough, United Kingdom

Jeffrey Pearson, Ph.D.
Chris Ward, B.Sc., M.Phil., Ph.D.*
Newcastle University
Newcastle upon Tyne, United Kingdom

ORCID ID: 0000-0002-6954-9611 (C.W.).
*Corresponding author (e-mail: chris.ward@ncl.ac.uk).

References

1. Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, et al.; ISARIC4C Investigators. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease: an international multicenter study. Am J Respir Crit Care Med 2020;202:1656–1665.

2. Sweet MP, Patti MG, Hoopes C, Hays SR, Golden JA. Gastroesophageal reflux and aspiration in patients with advanced lung disease. Thorax 2009;64:167–173.

3. Jones R, Krishnan A, Zeybel GL, Dookun E, Pearson JP, Simpson AJ, et al. Reflux in idiopathic pulmonary fibrosis: treatment informed by an integrated approach. ERJ Open Res 2018;4:00051-02018.

4. Dutta P, Funston W, Mossop H, Ryan V, Jones R, Forbes R, et al. Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis. Thorax 2019;74:346–353.

5. Almarco CV, Chey WD, Spiegel BM. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol 2020;115:1707–1715.

6. Lee SW, Ha EK, Yenioka AO, Moon SY, Kim SY, Koh HY, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut [online ahead of print] 30 Jul 2020; DOI: 10.1136/gutjnl-2020-322248.

Copyright © 2021 by the American Thoracic Society

Reply to Althuwaybi et al.

From the Authors:

Althuwaybi and colleagues propose an interesting hypothesis to explain the potential mechanism for increased risk of mortality following hospitalization for coronavirus disease (COVID-19) in patients with interstitial lung diseases (ILDs) (1). Unfortunately, in our study these data were not collected, and therefore, we cannot make comparisons with the control population. Gastroesophageal reflux is strongly linked to hiatus hernia, which is twice as prevalent in patients with idiopathic pulmonary fibrosis (IPF) as the general population (2, 3). It is therefore plausible that proton pump inhibitors (PPIs) may have been prescribed in excess in patients with ILD.

However, the cited evidence for a putative role of PPIs in pathophysiology is inconclusive and likely does not overcome the residual effect of significant comorbidities in our cohort. In an unpowered pilot randomized controlled trial into the effect of omeprazole therapy on cough in IPF, Dutta and colleagues reported safety events including three respiratory tract infections in the placebo group compared with six using omeprazole, which could be explained by chance (4). In a large population-based study of patients with IPF in a real-world clinical practice setting, PPI use was not associated with a difference in survival or the incidence of respiratory-related hospitalization compared with those not using PPIs (5). Althuwaybi and colleagues describe a dose response of PPIs with risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection reported in a large North American survey, as well as a retrospective health insurance database study in Korea that observed an association of PPI use with COVID-19 severity (6, 7). In contrast, the same Korean study found no association of PPIs with risk of infection; further study and meta-analyses will be required to build certainty on an effect. Lee and colleagues did observe a significant association between PPI use and severe outcomes in an adjusted model, particularly for a subgroup with <30 days of PPI records (7). Although the study included 132,316 individuals, a more limited 267 were currently using PPIs and were positive for SARS-CoV-2. A 79% greater risk of severe intervention was observed from 24/267 people with current PPI use (18/175 with <30 d of records), in comparison with 14/267 propensity-matched controls. The propensity-matched group had fewer significant comorbidities, and analyses did not adjust for lung function or body mass index, which we identify as important predictors of hospitalization outcomes. PPI use was not available for the individuals included in the study by Drake and colleagues, although the cited studies suggested little effect in past users or those with >30 days of treatment. It is likely that disease status, enhanced respiratory support, and significant comorbidities had a more substantial impact than PPI on outcomes in our cohort.

Furthermore, the role of PPIs in IPF pathogenesis remains uncertain. Post hoc analysis from international trials in IPF reported that pulmonary infections were higher in patients with advanced IPF (i.e., FVC <70%) who were receiving antacids compared with those not treated with antacids (8). However, PPIs have pleiotropic activity including antiinflammatory and antiproliferative effects (9). It is also worth noting, however, that although hiatus hernia has been independently linked to mortality in patients with IPF (2) and almost 5,000 participants in the AGES-Reykjavik birth cohort (3), in these uncontrolled studies, no association was found between PPI prescription and outcomes. The potential of antacid drugs to contribute to viral infections including COVID-19 has been the subject of some discussion (10). Thus, until further data are available, the potential adverse or favorable effects of PPIs in ILDs during the current pandemic remain to be determined, but understanding the balance of benefits and potential harms from antacids is imperative.

There are also a number of other potential mechanistic explanations why patients with ILD may have had poor outcomes.